A Randomized, Double-blind, Double-dummy, Multicenter Parallel Group Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil Versus Vardenafil PRN Versus Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving Erectile Function.

Trial Profile

A Randomized, Double-blind, Double-dummy, Multicenter Parallel Group Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil Versus Vardenafil PRN Versus Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving Erectile Function.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2014

At a glance

  • Drugs Vardenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms REINVENT
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jul 2009 Bayer HealthCare Pharmaceuticals Company added as trial affiliate as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Primary endpoint 'Erectile clinical response' has been met.
    • 19 Aug 2008 Status changed from in progress to completed according to a Bayer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top